BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tatli O, Dinler Doganay G. Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Molecules 2021;26:7561. [PMID: 34946644 DOI: 10.3390/molecules26247561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Barteselli G, Goodman GR, Patel Y, Caro I, Xue C, Mccallum S. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf 2022. [DOI: 10.1007/s40264-022-01248-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Ma H, Wu F, Bai Y, Wang T, Ma S, Guo L, Liu G, Leng G, Kong Y, Zhang Y. Licoricidin combats gastric cancer by targeting the ICMT/Ras pathway in vitro and in vivo. Front Pharmacol 2022;13:972825. [DOI: 10.3389/fphar.2022.972825] [Reference Citation Analysis]
3 Lieshout R, Faria AVS, Peppelenbosch MP, van der Laan LJW, Verstegen MMA, Fuhler GM. Kinome profiling of cholangiocarcinoma organoids reveals potential druggable targets that hold promise for treatment stratification. Mol Med 2022;28:74. [PMID: 35764936 DOI: 10.1186/s10020-022-00498-1] [Reference Citation Analysis]